These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 4907224)

  • 1. [Normal histology of the beta-cells during insulin secretion].
    Bänder A
    Acta Diabetol Lat; 1968 Oct; 5 Suppl 1():417-35. PubMed ID: 4907224
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ultrastructural events associated with the action of tolbutamide and glybenclamide on pancreatic B-cells in vivo and in vitro].
    Orci L; Stauffacher W; Renold AE; Beaven D; Lambert A; Rouiller C
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():271-374. PubMed ID: 4906021
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of increasing concentrations of glucose on insulin secretion. Synergy between glucose and hypoglycemic sulfonamides].
    Loubatières A; Mariani MM; Chapal J
    C R Seances Soc Biol Fil; 1968; 162(8):1575-80. PubMed ID: 4238184
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulfonamides].
    Pfeiffer EF
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():477-502. PubMed ID: 4906024
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental study of a new especially active hypoglycemic sulfonamide, HB-419 or Glibenclamide].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Chapal J
    Diabetologia; 1969 Feb; 5(1):1-10. PubMed ID: 4907149
    [No Abstract]   [Full Text] [Related]  

  • 6. Pirogliride: an oral hypoglycemic drug which accelerates glucose usage and insulin secretion by islets of Langerhans.
    Zawalich WS; Weill VA; Matschinsky FM
    Diabetes; 1980 May; 29(5):410-2. PubMed ID: 6991332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative studies on the effect of oral antidiabetics upon isolated rat islets of Langerhans].
    Tjioe TO; Puchinger H; Wacker A
    Hoppe Seylers Z Physiol Chem; 1970 Mar; 351(3):313-9. PubMed ID: 4911893
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on the synthesis and release of insulin from the beta cells of the pancreatic islets].
    Yokoo S; Okumura K
    Nihon Naibunpi Gakkai Zasshi; 1968 Oct; 44(7):728-32. PubMed ID: 4180484
    [No Abstract]   [Full Text] [Related]  

  • 9. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytology of beta-cells in rabbit pancreas pieces incubated in vitro; Effects of glucose and tolbutamide.
    Findlay JA; Gill JR; Irvine G; Lever JD; Randle PJ
    Diabetologia; 1968 Jun; 4(3):150-60. PubMed ID: 4902711
    [No Abstract]   [Full Text] [Related]  

  • 11. Beta cell secretion--from the standpoint of a pathobiologist.
    Lacy PE
    Diabetes; 1970 Dec; 19(12):895-905. PubMed ID: 4924734
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative study on the effects of a hypoglycemic 2-substituted-2-imidazoline derivative (DG-5128) and tolbutamide on insulin secretion from and insulin synthesis in the isolated rat pancreatic islets.
    Kameda KY; Koyama I; Abiko Y
    Biochim Biophys Acta; 1981 Oct; 677(2):263-8. PubMed ID: 7028134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the beta-cytotrophic effect of a new sulfonylurea derivative, glibornuride, and tolbutamide].
    Bottermann P; Souvatzoglou A; Schwarz K; Rettig M
    Klin Wochenschr; 1971 Jul; 49(13):769-70. PubMed ID: 4935073
    [No Abstract]   [Full Text] [Related]  

  • 14. [Insulin liberation from the pancreas by sulfonylurea].
    Pfaff W; Schöne HH
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1445-8. PubMed ID: 4899084
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 16. [Insulin secretion in the clinical stages of diabetes (with glucose tolerance test abnormalities)].
    Vague P; Vague J
    Journ Annu Diabetol Hotel Dieu; 1972; 13(0):55-65. PubMed ID: 4605752
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Alric R; Chapal J
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1354-63. PubMed ID: 4899083
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of the daily injection of tolbutamide into pregnant rats on the pancreatic insulin content of their offspring.
    Sodoyez JC; Sodoyez-Goffaux FR
    Metabolism; 1973 Nov; 23(2):1389-93. PubMed ID: 4584187
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction in the activity of the pancreatic islets induced in normal rodents by prolonged treatment with derivatives of sulfonylurea.
    Sodoyez JC; Sodoyez-Goffaux F; Dunbar JC; Foa PP
    Diabetes; 1970 Sep; 19(9):603-9. PubMed ID: 4918835
    [No Abstract]   [Full Text] [Related]  

  • 20. [Stimulation of insulin secretion in vitro by a new, highly-active antidiabetic].
    Schwarz H; Ammon J; Yeboah JE; Hildebrandt HE; Pfeiffer EF
    Diabetologia; 1968 Jan; 4(1):10-5. PubMed ID: 4907146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.